Homepage
Medication Guide
Dosage and Administration of Ceritinib (Zykadia)
Ceritinib (Zykadia) is a targeted therapy indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). As a second-generation ALK inhibitor, ...
501
Monday, November 24th, 2025, 09:17
What are the Indications for Ceritinib (Zykadia)?
Ceritinib (Zykadia) is a targeted therapy developed by Novartis, specifically indicated for the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. As a crucial anticancer...
501
Monday, November 24th, 2025, 09:14
What are the purchasing channels for Ceritinib (Zykadia)?
Ceritinib (Zykadia) is a targeted therapy for ALK-positive non-small cell lung cancer (NSCLC), providing patients with a crucial treatment option. During the process of obtaining the medication, patie...
501
Monday, November 24th, 2025, 09:11
Dosage and Administration of Dayvigo (Lemborexant)
Dayvigo (lemborexant) is an orexin receptor antagonist that was approved by the U.S. FDA in 2019 for the treatment of insomnia in adults. As a novel sleep-aid medication, it exerts its therapeutic eff...
502
Friday, November 21st, 2025, 13:17
How to Use Miglustat (Zavesca)
Miglustat (Zavesca) is a glucosylceramide synthase inhibitor that was first approved in the United States in 2003. As a monotherapy, this medication is indicated for adult patients with mild to modera...
502
Friday, November 21st, 2025, 13:14
What Kind of Medicine is Miglustat (Zavesca)?
Miglustat (Zavesca) is an innovative glucosylceramide synthase inhibitor, which was first approved in the United States in 2003.What Kind of Medicine is Miglustat (Zavesca)?Main Therapeutic AreasMiglu...
501
Friday, November 21st, 2025, 13:10
How to Purchase Miglustat (Zavesca)
Miglustat (Zavesca) is a glucosylceramide synthase inhibitor. It is indicated as monotherapy for adult patients with mild to moderate Type 1 Gaucher disease, and is only used in patients who cannot re...
502
Friday, November 21st, 2025, 13:05
Side Effects of Quizartinib
Quizartinib is an oral kinase inhibitor primarily indicated for the treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML). As a targeted therapy, it offers therapeutic efficacy a...
501
Friday, November 21st, 2025, 13:01
What are the precautions for taking Quizartinib?
Quizartinib is a selective FLT3 kinase inhibitor indicated for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). When used in combination with standa...
500
Friday, November 21st, 2025, 11:57
Dosage and Administration of Quizartinib
Quizartinib is a kinase inhibitor targeting the FLT3 receptor, which was first approved in the United States in 2023. In combination with standard induction therapy using cytarabine and anthracyclines...
503
Friday, November 21st, 2025, 11:52
25 / 184
1837 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved